Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Futura Medical ( (GB:FUM) ) has issued an update.
Futura Medical announced successful results from their WSD4000 Home User study, demonstrating positive impacts on sexual function in women suffering from sexual dysfunction. Following these results and market research, the company plans to move forward with an Early Feasibility Study in 2025, positioning WSD4000 as a potentially groundbreaking topical treatment in an underserved market, with the aim to refine the product and advance towards commercialization.
More about Futura Medical
Futura Medical plc is a consumer healthcare company specializing in the development and global commercialization of innovative sexual health products. Its core strength lies in research, development, and commercialization of topically delivered gel formulations, including leading products such as Eroxon® for erectile dysfunction and WSD4000 for female sexual dysfunction. The company operates in a market where sexual health issues are prevalent, with significant unmet needs among both men and women.
YTD Price Performance: -4.03%
Average Trading Volume: 660,359
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: £92.25M
See more data about FUM stock on TipRanks’ Stock Analysis page.